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OBJECTIVES: The relationships between the adipokines tumor necrosis factor (TNF)-α and adiponectin and the
parameters of glucose homeostasis and severity of liver disease were assessed in nonobese
nondiabetic subjects with nonalcoholic steatohepatitis (NASH).
METHODS: A frequently sampled intravenous glucose tolerance test, serum cytokine measurement, and 7-day
alimentary record were performed in 20 biopsy-proven NASH patients and 45 age-, sex-, and
BMI-matched controls (30 insulin sensitive and 15 insulin resistant).
RESULTS: Patients with NASH had impaired pancreatic β-cell function compared with both insulin-sensitive
(adaptation index, AI: 97.7 ± 17.7 vs 307.4 ± 24.1 min–2 mmol–1 L; p = 0.00001) and
insulin-resistant (adaptation index, AI: 97.7 ± 17.7 vs 201.4 ± 41.1 min–2 mmol–1 L; p = 0.001)
controls. Serum adiponectin levels were also significantly lower in the NASH group than in the two
control groups and correlated with adaptation index and with the severity of hepatic steatosis,
necroinflammation, and fibrosis. When NASH patients were grouped according to the severity of
histological liver damage, adiponectin was the only variable discriminating patients with higher
necroinflammatory grade and fibrosis score from those with milder lesions.
CONCLUSIONS: β-cell secretory impairment is present in nonobese patients with NASH before glucose intolerance
appears and may contribute to their increased risk for developing diabetes. Hypoadiponectinemia is
a feature of NASH and may have a pathogenetic role in β-cell dysfunction and in hepatic
necroinflammation and fibrosis, independently of insulin resistance, visceral fat accumulation,
TNF-α axis activity, and dietary habits. Our findings provide further rationale for therapeutic
approaches aimed at increasing adiponectin levels together with restoring β-cell function and
insulin sensitivity.
(Am J Gastroenterol 2005;100:2438–2446)
INTRODUCTION
Nonalcoholic steatohepatitis (NASH) is a chronic liver
disease, histologically resembling alcoholic liver disease,
encountered in individuals without significant alcohol con-
sumption; it is part of a spectrum of liver damage, rang-
ing from simple steatosis to advanced fibrosis and cirrhosis,
named nonalcoholic fatty liver disease (NAFLD). NAFLD
has become the most common chronic liver disease in West-
ern countries, with a prevalence of 20% among adults in
the United States (1). NASH is strongly associated with the
metabolic syndrome, being present from early stages of the
syndrome until overt type 2 diabetes mellitus has appeared,
but the mechanism(s) underlying this association are not com-
pletely clear. In the NHANES III study, adults with NAFLD
were more than twice as likely to have diabetes than those
without NAFLD after adjustment for BMI, age, gender, and
race (2); in two large, prospective cohort studies, high ala-
nine aminotransferase levels predicted the subsequent devel-
opment of type 2 diabetes mellitus independently of classical
risk factors (3, 4).
Conversely, the presence of type 2 diabetes conveys a high
risk for an aggressive outcome in NAFLD, doubling the risk
for cirrhosis and increasing liver-related mortality 20-fold (5–
7). The factor(s) responsible for the progression of metabolic
and hepatic disease in NAFLD are poorly understood. Insulin
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resistance is a hallmark of NASH, and current therapeutic ap-
proaches aim at improving insulin sensitivity in patients with
overt obesity and diabetes (8), but no systematic evaluation of
β-cell function in NASH is available and little is known about
glucose homeostasis in NASH at earlier stages of metabolic
disease, i.e., before diabetes mellitus and obesity appear. An
impairment in β-cell function predicts the development of di-
abetes mellitus in different populations (i.e., older individuals
and women with a history of gestational diabetes or polycystic
ovary syndrome) independently of the degree of insulin resis-
tance (9, 10). Furthermore, adipocyte-derived cytokines, or
adipokines, in particular tumor necrosis factor (TNF-α) and
adiponectin, have been recently implicated in the pathogene-
sis of type 2 diabetes mellitus and NASH, via their metabolic
and pro-/anti-inflammatory activities (11–13).
This study assesses the relationships between two
adipokines, TNF-α and adiponectin, and the severity of liver
disease and factors regulating glucose homeostasis (i.e., tis-
sue insulin sensitivity, pancreatic β-cell function, and glucose
effectiveness) in nonobese nondiabetic patients with biopsy-
proven NASH.
MATERIALS AND ME THODS
Subjects
Twenty patients (mean age ± SEM, 37 ± 3 yr, BMI 25.5 ± 0.7
kg/m2) attending our Liver Unit during the years 2003–2004
were selected according to the following criteria: persistently
(at least 12 months) elevated aminotransferases and ultra-
sonographic presence of bright liver without any other liver
or biliary tract disease. Exclusion criteria were: a history of
alcohol consumption >40 g/wk (assessed by a detailed in-
quiry and a validated questionnaire filled in daily for 1 wk
by the patients); a body mass index (BMI) ≥30 kg/m2 for
males and ≥28 for females; positive serum markers of viral,
autoimmune, or celiac disease; abnormal copper metabolism
or thyroid function tests; a diagnosis of overt diabetes mel-
litus (fasting plasma glucose ≥126 mg/dL or ≥200 mg/dL
at +2h on a standard oral glucose load, OGTT); serum total
cholesterol ≥200 mg/dL, serum triglycerides ≥200 mg/dL;
and exposure to occupational hepatotoxins or to drugs known
to be steatogenic or to affect glucose metabolism. Mutations
in the hemochromatosis HFE and TRF2 genes were detected
in patients and controls using a single, multiplex amplifica-
tion reaction and pre-made, ready-to-use teststrips (Nuclear
Laser Medicine, Milan, Italy). Liver biopsy specimens were
obtained from all patients and were blindly examined by a
single pathologist (ED). Fatty infiltration, necroinflamma-
tion, and fibrosis were assessed as proposed by Brunt (14).
Minimal histologic criteria for steatohepatitis were: steatosis
involving al least 5% of hepatocytes, lobular inflammation,
and zone 3 ballooning degeneration. Liver iron concentration
(LIC) was determined on 2-mg dry weight tissue by atomic
absorption spectroscopy. The hepatic iron index (HII) was
obtained by dividing LIC (µmol/g) by age (years; normal
range below 0.5).
The controls consisted of 30 healthy insulin-sensitive (de-
fined by an insulin sensitivity index SI > 4.83 × 10–4 min–1
µU–1 mL–1) and 15 insulin-resistant (defined by an insulin
sensitivity index SI < 4.83 × 10–4 min–1 µU–1 mL–1) in-
dividuals matched for age, sex, and BMI with normal liver
enzymes and abdominal ultrasound scans (Table 1). The cut-
off value (4.83 × 10–4 min–1 µU–1 mL–1) was obtained by
an analysis of the SI of controls from this and other studies
(8, 25). Patients and controls gave their consent to the study,
which was conducted according to the Helsinki Declaration.
Alimentary Record
Patients and controls were instructed to fill in a 7-day di-
etary record during a 30-minute individual session with a
trained nutritionist; a list of foods was designed, and for each
item, different portion sizes were specified according to the
EPIC study (15, 16). The recorded period included a com-
plete week, and the record was collected within 1 wk of the
glucose tolerance tests. The diet record was analyzed using
the WinFood database (Medimatica, Teramo, Italy) accord-
ing to the table of food consumption of the Italian National
Institute of Nutrition (17) and Food Composition Database
for Epidemiological Study in Italy (18).
Cytokine Measurements
Serum TNF-α and adiponectin were measured by sandwich
enzyme-linked immunosorbent assay (R&D System Europe
Ltd, Abingdon, UK). For TNF-α, the kit has a sensitivity of
0.12 pg/mL in a 200-µL sample size and a range of 0.5–32
pg/mL. The intra- and inter-assay coefficients of variation
were 5.9% and 12.6%, respectively. For human adiponectin,
the kit has a sensitivity of 0.25 pg/mL in a 50-µL sample size
and a range of 3.9–250 ng/mL. The intra- and inter-assay
coefficients of variation were 3.4% and 5.8%, respectively.
All samples were diluted by 1/100.
Oral Glucose Tolerance Test (OGTT)
After completion of the alimentary record and of baseline
anthropometric measures and blood chemistry tests, patients
and controls underwent a standard 75-g oral glucose tolerance
test (OGTT), with measurement of plasma glucose and serum
insulin concentrations at 0, 30, 60, 90, and 120 min.
Frequently Sampled Intravenous Glucose Tolerance
Test (FSIGT)
After an overnight fast, an intravenous glucose tolerance test
(0.3 g/kg body weight glucose bolus administered at time
zero) was performed. Blood samples were collected in the
following 3 h for glucose, insulin, and C-peptide concen-
tration measurements. Data analysis by the minimal model
technique yielded the following parameters of glucose home-
ostasis (19, 20): glucose tolerance index (KG), which repre-
sents the rate of disappearance of glucose from peripheral
blood and is computed as the slope of the logarithm of the
glucose concentration values between 12 and 40 min; insulin
sensitivity index (SI), which describes the ability of tissues
to dispose of glucose under the action of insulin; and glucose
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Table 1. Baseline Characteristics of Patients with NASH and Controls
NASH Insulin-Resistant Insulin-Sensitive P NASH vs
(n = 20) Controls (n = 15) Controls (n = 30) Healthy
Age (yr) 37 ± 3 40 ± 3 36 ± 3 0.822
Sex (M/F) 19/1 13/2 28/2 0.999
BMI (kg/m2) 25.5 ± 0.7 25.3 ± 0.6 25.3 ± 0.5 0.812
Family history of Type 2 diabetes (n◦ subjects) 3 4 4 0.631
Smokers (n◦ subjects) 4 3 6 0.999
Waist (cm) 90 ± 3 91 ± 3 87 ± 2 0.390
Systolic blood pressure (mmHg) 131 ± 3 130 ± 3 127 ± 3 0.370
Diastolic blood pressure (mmHg) 90 ± 2 89 ± 2† 77 ± 1 0.0001
Triglycerides (mg/dL)∗ 99 ± 13 103 ± 17 76 ± 6 0.080
Total cholesterol (mg/dL)† 175 ± 10 160 ± 12 169 ± 6 0.471
HDL cholesterol (mg/dL)† 47 ± 2 44 ± 3† 56 ± 4 0.089
LDL cholesterol (mg/dL)† 107 ± 10 105 ± 10 102 ± 5 0.444
Uric acid (mg/dL)† 6.18 ± 0.29 6.21 ± 0.35† 5.26 ± 0.22 0.013
Glucose (mg/dL) 92 ± 3 93 ± 3 86 ± 2 0.104
Insulin (µU/mL) 13.7 ± 2.1 12.1 ± 2.3† 7.2 ± 1.1 0.004
Albumin (g/dL) 4.8 ± 0.1 4.8 ± 0.1 5.0 ± 0.1 0.212
AST (U/L) 37 ± 3 25 ± 4∗ 26 ± 3 0.026
ALT (U/L) 87 ± 8 35 ± 4∗ 33 ± 4 0.0001
GGT (U/L) 87 ± 18 38 ± 8∗ 41 ± 4 0.006
ALP (U/L) 83 ± 8 50 ± 8 52 ± 7 0.011
HFE mutation (H63D) heterozygotes (n◦ subjects) 4 1 4 0.703
Serum iron (µg/dL) 97 ± 4 99 ± 4 88 ± 4 0.146
Ferritin (µg/L) 171 ± 21 140 ± 31 135 ± 20 0.227
Transferrin (% sat) 33 ± 1 30 ± 3 29 ± 2 0.131
TNF-α (pg/mL) 1.05 ± 0.14 1.08 ± 0.16 0.99 ± 0.08 0.525
Adiponectin (ng/mL) 4,378 ± 434 6,780 ± 511∗,† 9,850 ± 940 0.00001
Data are presented as mean ± SEM.
∗p < 0.05 versus NASH.
†p < 0.05 versus healthy controls.
effectiveness (SG), which represents the ability of glucose per
se to mediate its own uptake by tissues by mass action and
to suppress endogenous glucose production independently
of dynamic insulin action (19). Advantages and limitations
of this technique have been extensively described in previ-
ous publications (20). Insulin secretion and liver degradation
were described by: acute insulin response to glucose bolus
(AIRG), calculated by averaging the incremental concentra-
tion of insulin between 3 and 10 min after glucose injection;
β-cell sensitivities to glucose (φ1 and φ2), i.e., the ability of
glucose to stimulate early (first-phase) and delayed (second-
phase) C-peptide secretion; and average hepatic insulin ex-
traction (Hmean), i.e., the ability of the liver to extract insulin
from the portal blood. The overall metabolic status was de-
scribed by two indexes, which relate β-cell insulin secretion
and post-hepatic delivery to insulin resistance: the disposi-
tion index (DI), calculated by multiplying SI by AIRG (21),
and the adaptation index (AI), calculated by multiplying SI
by φ1 (22). These indexes describe the ability of the system
to compensate for changes (i.e., a reduction) in insulin sen-
sitivity by adapting (i.e., increasing) insulin secretion, and
represent integrated markers of β-cell function (23).
Statistical Analyses
Data are expressed as mean ± SEM. Differences between
groups were analyzed by analysis of variance (ANOVA), fol-
lowed by Student-Neuman-Keuls test, when variables were
normally distributed; otherwise the Mann-Whitney test was
used. Normality was evaluated by the Shapiro-Wilk test. The
Chi-square test or Fisher’s exact test was used to compare
categorical variables, as appropriate. The Spearman rank cor-
relation coefficient was used to estimate the relationship be-
tween different histological, anthropometric, dietary, and bio-
chemical variables. Multiple regression analysis was applied
when multiple associations were detected, after log transfor-
mation of skewed data. Differences were considered statisti-
cally significant if p < 0.05.
RESULTS
Baseline Parameters
Baseline features of NASH patients and controls are reported
in Table 1. Patients and insulin-resistant controls had higher
mean diastolic pressures, fasting serum insulin levels, and
uric acid levels than insulin-sensitive controls.
There was no significant difference in the number of smok-
ers among the three groups (4 patients and 6 controls). Four
patients and five controls were heterozygous carriers of the
H63D mutation of the HFE gene (p = N.S.).
Adopting the Adult Treatment Panel III criteria for the
clinical definition of the metabolic syndrome (24), 15
patients had hypertension (systolic/diastolic blood pres-
sure 130/85 mmHg), one was hypertriglyceridemic (fast-
ing plasma triglycerides 150 mg/dL), five had low plasma
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Table 2. Minimal Model Parameters of Patients with NASH and Controls
NASH Insulin-Resistant Insulin-Sensitive P NASH vs
(n = 20) Controls (n = 15) Controls (n = 30) Healthy
SI (10–4 min–1 µU–1 mL–1) 3.93 ± 0.55 3.19 ± 0.69† 7.91 ± 0.61 0.0001
SG (min–1) 0.022 ± 0.003 0.020 ± 0.002 0.025 ± 0.001 0.277
φ1 (pmol min–1mg–1dL) 76.05 ± 9.93 114.01 ± 25.14 125.50 ± 10.52 0.003
φ2 (pmol min–2mg–1dL) 0.051 ± 0.014 0.050 ± 0.004 0.048 ± 0.006 0.826
AIRG (µU/mL) 72.2 ± 16.6 66.9 ± 18.7 64.6 ± 6.95 0.660
DI (min–1) 228.2 ± 45.6 321.7 ± 51.7∗,† 488.5 ± 43.1 0.0001
AI (min–2 mmol–1 L) 97.7 ± 17.7 201.4 ± 41.1∗,† 307.4 ± 24.1 0.00001
Hmean (%) 69 ± 4 78 ± 4 72 ± 4 0.544
KG (%/min) 1.71 ± 0.23 2.01 ± 0.36 2.18 ± 0.17 0.090
Data are presented as mean ± SEM.
∗p < 0.05 versus NASH.
†p < 0.05 versus healthy controls.
HDL-cholesterol (HDL-C <40 mg/dL in men and <50
mg/dL in women), five had impaired glucose regulation (one
had impaired fasting glycemia and five had impaired glucose
tolerance on the OGTT; see below), and one had abdomi-
nal obesity (waist circumference >102 cm in men and >88
cm in women). Only four patients had the whole picture of
the metabolic syndrome (at least three criteria met), and the
remaining patients had only one (six patients) or two (10
patients) clinical features of the syndrome.
Cytokine Measurements
Serum adiponectin levels were significantly lower in patients
with NASH than in insulin-resistant (4,378 ± 434 vs 6,780 ±
511 ng/mL; p = 0.001) and insulin-sensitive controls (4,378
± 434 vs 9,850 ± 940 ng/mL; p = 0.00001), while there was
no difference in serum TNF-α among the three groups.
Histopathology
Liver biopsy specimens were compatible with a diagnosis of
NASH in all 20 patients: fatty infiltration was mild (involving
5–33% of hepatocytes) in 7 patients, moderate (33–66% of
hepatocytes) in 6 patients, and severe (>66% of hepatocytes
involved) in 7 patients. Necroinflammatory activity was grade
1 in 8 patients, grade 2 in 6 patients, and grade 3 in 6 patients.
Fibrosis was stage 0 in 9 patients, stage 1 in 2 patients, stage
2 in 4 patients, and stage 3 in 5 patients; cirrhotic changes
were absent in our patients. Liver iron concentration was 20
± 2 µmol/g dry weight and hepatic iron index was 0.64 ±
0.03.
Alimentary Record
The daily total energy and macronutrient intakes of patients
with NASH and controls were similar: total calories: 2,510
± 123 versus 2,498 ± 148 kcal, p = 0.898; carbohydrate:
50 ± 2 versus 48 ± 2% kcal, p = 0.598; protein: 17 ± 3
versus 19 ± 2% kcal, p = 0.568; fat: 33 ± 2 versus 32 ± 1%
kcal, p=0.673. Patients with NASH consumed a diet richer in
saturated fat and poorer in polyunsaturated fat than controls,
when expressed as both the percentage of total calories and
the percentage of total fat intake, as previously reported (25):
SFA: 13.5 ± 0.8 versus 9.1 ± 0.5%% tot kcal, p = 0.000;
PUFA: 3.5 ± 0.3 versus 5.0 ± 0.4% tot kcal, p = 0.000. The
polyunsaturated to saturated fat ratio was also significantly
lower in the NASH group (P/S ratio: 0. 24 ± 0.03 vs 0.47 ±
0.03, p = 0.0002).
Daily cholesterol intake was higher in patients than in con-
trols: 506 ± 28 versus 410 ± 28 mg/d (p = 0.002). NASH
patients also had a significantly lower daily intake of the an-
tioxidant vitamin E (5.4 ± 0.5 vs 8.6 ± 0.6 mg, p = 0.0001),
while there was no difference in the intakes of vitamin A and
C. Dietary habits of controls were comparable to those of a
large sample of healthy individuals of the Piedmont popula-
tion, as assessed by a recent alimentary survey (16).
Oral Glucose Tolerance Test
No patient was classified as diabetic, five patients had im-
paired glucose tolerance (IGT) according to ADA Rec-
ommendations (26), and one patient had impaired fasting
glycemia (fasting plasma glucose ≥110 mg/dL but <126
mg/dL).
Minimal Model Parameters
Patients showed a lower glucose tolerance (KG) than con-
trols, although the difference was not statistically significant
(Table 2). SI was markedly lower in patients than in insulin-
sensitive controls, while SG was similar. First-phase β-cell
sensitivity to glucose, φ1, was significantly lower in patients
than in insulin-sensitive controls, though the absolute values
of the insulin concentration in the early phase (AIRG) were
not different. Both the disposition index (DI) and adaptation
index (AI) were significantly lower in patients than in the two
control groups, with no difference between patients with a
family history of type 2 diabetes mellitus and those without
(not shown). Hepatic insulin extraction was similar in the
three groups.
Normotolerant versus Impaired Glucose Tolerant Patients
Compared with healthy controls, patients with normal glu-
cose tolerance (NGT; n = 15) displayed lower insulin sensi-
tivity (SI: 4.46 ± 0.55 vs 7.91 ± 0.61 10–4 min–1 µU–1 mL–1;
p = 0.0001), disposition index (DI: 259.9 ± 48.9 vs 488.5
± 43.1 min−1, p = 0.002), and adaptation index (AI: 111.1
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± 17.7 vs 307.4 ± 24.1 pmol min–1mg–1 dL; p = 0.0001),
while there was no difference in any other anthropometrical,
biochemical, dietary, or histological parameters.
NGT patients were not significantly different from IGT
patients in SI (4.46 ± 0.55 vs 2.34 ± 0.40 10–4 min–1 µU–1
mL–1; p = 0.070) or adaptation index (AI: 111.1 ± 17.7 vs
57.4 ± 10.1 pmol min–1mg–1 dL; p = 0.084), or in any of
the other parameters.
Correlations Between Anthropometric, Metabolic,
and Histological Parameters
Insulin sensitivity index (SI) correlated with waist circum-
ference (rs = –0.53; p = 0.014), serum TNF-α (rs = –0.49;
p = 0.027), and saturated fat intake expressed as a percentage
of calories (rs = –0.59; p = 0.005). On multiple regression
analysis, only saturated fat intake (β = –0.54; p = 0.009)
and waist circumference (β = –0.49; p = 0.010) indepen-
dently predicted changes in insulin sensitivity. Adaptation
index (AI) correlated with serum adiponectin (rs = 0.60;
p = 0.005), serum TNF-α (rs = –0.47; p = 0.038), ALT levels
(rs = –0.45; p = 0.047), and liver fatty infiltration (rs = –0.59;
p = 0.008), but not with any other variable. On multiple re-
gression analysis, only serum adiponectin (β = 0.48; p =
0.031) and serum TNF-α (β = –0.42; p = 0.033) indepen-
dently predicted changes in adaptation index.
Table 3. Main Clinical, Biochemical, and Model Characteristics of NASH Patients with Histological Necroinflammatory Grade 1 and Grade
2 + 3 and of Controls
Insulin-Sensitive NASH Grade 1 NASH Grade 2–3 P Grade 1 vs
Controls (n = 30) (n = 8) (n = 12) Grade 2–3
Age (yr) 36 ± 3 38 ± 3 37 ± 5 0.767
BMI (kg/m2) 25.3 ± 0.5 25.4 ± 0.7 26.2 ± 0.9 0.274
Waist (cm) 87 ± 2 90 ± 2 92 ± 3 0.627
Impaired glucose tolerance (n◦ subjects) 0 1 4 0.603
Triglycerides (mg/dL) 76 ± 6 105 ± 21 92 ± 12 0.498
Total cholesterol (mg/dL) 169 ± 6 181 ± 10 166 ± 19 0.392
Uric acid (mg/dL) 5.26 ± 0.22 6.11 ± 0.39∗ 6.28 ± 0.15∗ 0.720
AST (U/L) 26 ± 15 37 ± 4† 37 ± 3 0.966
ALT (U/L) 33 ± 20 81 ± 13‡ 96 ± 8‡ 0.371
GGT (U/L) 41 ± 20 114 ± 25† 45 ± 17 0.096
ALP (U/L) 52 ± 31 94 ± 13 71 ± 8 0.135
Albumin (g/dL) 5.0 ± 0.1 4.8 ± 0.1 4.9 ± 0.1 0.184
Serum iron (µg/dL) 88 ± 4 101 ± 4 92 ± 6 0.227
Ferritin (µg/L) 135 ± 20 147 ± 23 210 ± 39 0.184
Transferrin (% sat) 29 ± 2 35 ± 4 29 ± 2 0.082
Liver iron concentration (µmol/g dry weight) – 21 ± 4 15 ± 3 0.238
Hepatic iron index – 0.64 ± 0.13 0.48 ± 0.05 0.204
TNF-α (pg/mL) 0.99 ± 0.08 0.94 ± 0.09 1.24 ± 0.3 0.292
Adiponectin (ng/mL) 9,850 ± 940 5,061 ± 529∗ 3,440 ± 286‡ 0.012
SI (10–4 × min–1 × µU–1 × mL−1) 7.91 ± 0.61 4.18 ± 0.81† 3.62 ± 0.75† 0.641
φ1 (pmol × min–1mg−1dL) 125.50 ± 10.52 83.94 ± 17.26∗ 69.59 ± 19.13∗ 0.516
DI (min–1) 488.5 ± 43.1 235.9 ± 45.7∗ 201.4 ± 72.9∗ 0.731
AI (min–2 × mmol–1 × L) 307.4 ± 24.1 120.4 ± 27.4‡ 80.1 ± 38.2‡ 0.450
Hmean (%). 72 ± 4 77 ± 6 61 ± 7 0.124
SG (min–1) 0.025 ± 0.001 0.023 ± 0.001 0.016 ± 0.002 0.101
KG (%/min) 2.18 ± 0.17 1.73 ± 0.21 1.60 ± 0.14 0.603
Data are presented as mean ± SEM.
∗p < 0.05 versus controls.
†p < 0.01 versus controls.
‡p < 0.001 versus controls.
Liver fatty infiltration, expressed as the percentage of hep-
atocytes involved, correlated with adiponectin levels (rs =
–0.60; p = 0.005), adaptation index (rs = –0.59; p = 0.008),
and waist circumference (rs = –0.50; p = 0.025), but not
with other parameters. On multiple regression analysis, only
serum adiponectin levels were independently associated with
liver fatty infiltration (β = –0.50; p = 0.024).
Inflammatory grade correlated with adiponectin levels
(rs = –0.51; p = 0.029) but not with any other parameter.
Similarly, fibrosis score correlated with adiponectin levels
(rs = –0.54; p = 0.012) but not with steatosis, inflammation,
or any other clinical or biochemical parameter.
To further explore the relationships between liver histol-
ogy and the variables assessed, patients were grouped into
2 categories on the basis of the severity of inflammation:
mild (grade 1; n = 8) and moderate-severe (grade 2–3;
n = 12). The latter group had lower adiponectin levels than
the former, but did not differ in any other anthropometrical,
biochemical, or dietary parameter (the main characteristics
of the two groups and of the controls are reported in Table 3).
The mild inflammation group also had lower adiponectin lev-
els than insulin-resistant controls: (5,061 ± 529 vs 6,780 ±
511 ng/mL; p = 0.044).
Patients were then divided into 2 subgroups on the ba-
sis of fibrosis score: mild-absent (score 0–1; n = 11) and
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Figure 1. Serum adiponectin levels of NASH patients, according to
fibrosis stage, and of insulin-sensitive controls: absent-mild fibrosis
(stage 0–1), moderate-severe fibrosis (stage 2–3). Data are presented
as mean ± SEM. p < 0.01 versus controls, p < 0.005 versus
NASH stage 0–1.
moderate-severe (score 2–3; n = 9). The moderate-severe
fibrosis group had significantly lower adiponectin levels than
the former (Fig. 1), but did not differ in any other anthropo-
metrical, biochemical, or dietary parameter (the main char-
acteristics are reported in Table 4). The mild-absent NASH
group had lower adiponectin levels than insulin-resistant con-
trols as well: 5,045 ± 433 versus 6,780 ± 511 ng/mL; p =
0.021.
DISCUSSION
The main determinants of glucose homeostasis were assessed
in 20 patients with biopsy-proven NASH and were correlated
with dietary habits, circulating levels of two adipokines, and
liver histology. Nonobese nondiabetic patients were selected,
since obesity and diabetes can, per se, affect β-cell function
and serum adipokine levels (9, 27); furthermore, NAFLD is
considered an early predictor of the future development of
overt metabolic disorders in normal-weight glucose-tolerant
individuals (28).
A novel finding of our study is that a marked β-cell secre-
tory dysfunction was detectable in NASH long before glucose
intolerance appeared, thus giving a strong pathophysiological
basis, together with insulin resistance, for the increased risk
for developing diabetes observed in this population (2, 3). In
this context, we evaluated the disposition and adaptation in-
dexes, which represent insulin secretion in relation to ambient
insulin sensitivity and provide an accurate figure of pancre-
atic action (20–22). These indexes were lower in patients with
NASH than in insulin-sensitive controls, and were also lower
than those of matched insulin-resistant controls, indicating
β-cell failure to compensate for decreased insulin sensitivity
long before glucose intolerance appears in individuals at high
risk for developing diabetes mellitus (9). The relevance of β-
cell failure to the pathogenesis of diabetes in liver disease has
been clearly demonstrated in cirrhosis, where improving in-
sulin sensitivity by liver transplantation cures hepatogenous
diabetes in only a portion of patients, while the others remain
diabetic due to persistent β-cell secretory dysfunction (29).
Our finding highlights the importance of evaluating the ef-
fect of proposed therapies on β-cell function in NASH, since
most of the current therapeutic approaches aim at improving
insulin sensitivity, but their effects on islet cell secretion, as
well as on the long-term progression of metabolic disease,
are unknown in these patients.
Both genetic and acquired factors may have been respon-
sible for β-cell dysfunction in our patients. It is well known
that family members of diabetics have a reduced ability of β
cells to compensate for impaired insulin sensitivity and are
at a greater risk for developing diabetes; however, only three
of our patients were first-degree relatives of diabetics, and
their β-cell function did not differ from the other patients
(not shown).
Impaired glucose tolerance may, per se, reduce β-cell func-
tion (21), but in our study, β-cell dysfunction was detectable
in the 15 patients with normal glucose tolerance as well.
Alimentary factors, in particular a diet high in saturated
fat, have been implicated in the pathogenesis of pancreatic
β-cell dysfunction in cell cultures and animal models (30,
31). Although saturated fat intake was higher in patients than
in controls, it correlated with the insulin sensitivity index,
as previously reported (25), and not with the β-cell function
indexes.
Our data suggest that the adipokines adiponectin and TNF-
α may be implicated in the β-cell dysfunction seen in NASH.
In fact, the adaptation index of our patients correlated with
adiponectin and with TNF-α levels, the latter, however, be-
ing comparable to those of controls: a likely explanation is
that, in the setting of hypoadiponectinemia, pancreatic islet
cells become more susceptible to harmful factors such as
visceral fat-released free fatty acids, TNF-α, and possibly
saturated fat intake. Consistent with our data, adiponectin
correlated with β-cell function indexes in healthy individu-
als and prevented pancreatic β-cell apoptosis in cell cultures
by suppressing TNF-α and free fatty acid–induced nuclear
factor (NF)-κB activation, a key mediator of inflammatory-
induced gene transcription (32, 33). Furthermore, thiazo-
lidinediones, a group of peroxisome proliferator-activated
receptor (PPAR)-γ agonists that enhance insulin sensitivity
and increase circulating adiponectin, were able to reduce islet
triglyceride content and restore impaired glucose-stimulated
insulin secretion in mice fed a high fat diet (34).
The adaptation index correlated with the severity of steato-
sis in patients with NASH. This finding may simply re-
flect the association of hypoadiponectinemia with both β-cell
dysfunction and liver fatty infiltration or, alternatively, β-
cell failure may directly contribute to liver fat accumulation
in NASH: in healthy humans, acute hyperinsulinemia sup-
presses VLDL production both directly, by modulating intra-
hepatic VLDL assembly, and indirectly, by reducing plasma
FFA availability (35), the latter ability being maintained in
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Table 4. Main Clinical, Biochemical and Model Characteristics of NASH Patients with Fibrosis Stage 0–1, Fibrosis Stage 2–3,
and of Controls
Insulin-Sensitive NASH Stage 0–1 NASH Stage 2–3 P Stage 0–1 vs
Controls (n = 30) (n = 11) (n = 9) Stage 2–3
Age (yr) 36 ± 3 38 ± 3 36 ± 4 0.697
BMI (kg/m2) 25.3 ± 0.5 25.4 ± 0.6 26.2 ± 1.1 0.461
Waist (cm) 87 ± 2 90 ± 2 92 ± 3 0.343
Impaired glucose tolerance (n◦ subjects) 0 2 3 0.999
Triglycerides (mg/dL) 76 ± 6 112 ± 15 75 ± 14 0.164
Total cholesterol (mg/dL) 169 ± 6 185 ± 9 156 ± 19 0.434
Uric acid (mg/dL) 5.26 ± 0.22 6.13 ± 0.31∗ 6.27 ± 0.38∗ 0.756
AST (U/L) 26 ± 15 37 ± 4 35 ± 3 0.983
ALT (U/L) 33 ± 20 80 ± 10∗ 97 ± 15∗ 0.367
GGT (U/L) 41 ± 20 115 ± 21∗ 66 ± 14 0.091
ALP (U/L) 52 ± 31 91 ± 11 66 ± 21 0.209
Albumin (g/dL) 5.0 ± 0.1 4.8 ± 0.1 4.9 ± 0.2 0.542
Serum iron (µg/dL) 88 ± 4 100 ± 4 88 ± 6 0.372
Ferritin (µg/L) 135 ± 20 141 ± 18 214 ± 46 0.129
Transferrin (% sat) 29 ± 2 35 ± 2 29 ± 3 0.094
Liver iron concentration (µmol/g dry weight) – 19 ± 3 15 ± 3 0.363
Hepatic iron index – 0.58 ± 0.11 0.48 ± 0.06 0.464
TNF-α (pg/mL) 0.99 ± 0.08 0.91 ± 0.08 1.30 ± 0.31 0.243
Adiponectin (ng/mL) 9,850 ± 940 5,045 ± 433† 3,234 ± 373‡ 0.002
SI (10–4 × min–1 × µU–1 × mL–1) 7.91 ± 0.61 4.22 ± 0.77† 3.50 ± 0.93† 0.558
φ1(pmol × min–1mg–1dL) 125.50 ± 10.52 82.72 ± 20.62∗ 70.97 ± 15.72∗ 0.667
DI (min–1) 488.5 ± 43.1 260.3 ± 73.64∗ 200.2 ± 70.3∗ 0.569
AI (min–2 × mmol–1 × L) 307.4 ± 24.1 125.6 ± 24.9‡ 80.8 ± 41.4† 0.342
Hmean (%) 72 ± 4 78 ± 4 64 ± 8 0.115
SG (min–1) 0.025 ± 0.001 0.023 ± 0.005 0.016 ± 0.002 0.165
KG (%/min) 2.18 ± 0.17 1.73 ± 0.21 1.54 ± 0.17 0.999
Data are presented as mean ± SEM.
∗p < 0.05 versus controls.
†p < 0.01 versus controls.
‡p < 0.001 versus controls.
obesity (36) and in type 2 diabetes (37). In NAFLD, the
suppressive effect of insulin on plasma FFA availability was
maintained during the first 2 h of euglycemic hyperinsuline-
mic clamp, and was then progressively lost (38). A blunting
of the early β-cell insulin secretion may thus enhance hep-
atic TG accumulation by increasing plasma FFA availability,
particularly in the setting of the exaggerated postprandial
triglyceride response seen in these patients (25).
The other novel finding of our study is the independent
association of hypoadiponectinemia with the severity of fi-
brosis deposition in patients with NASH. Previous studies re-
ported that hypoadiponectinemia was closely related to hep-
atic fat content in diabetic patients (39) and that adiponectin
delivery alleviated steatosis and LPS-induced liver injury in
animal models of fatty liver disease, through modulation of
TNF-α and PPAR-α activity (40, 41). Recently, Hui et al.
found that hypoadiponectinemia and insulin resistance in-
dependently predicted the severity of steatosis and necroin-
flammation in NAFLD, suggesting that low adiponectin lev-
els may be a feature of NASH (13). We found that, while the
severity of steatosis paralleled the degree of insulin resistance
and hypoadiponectinemia, only adiponectin levels correlated
inversely with the severity of necroinflammation and of fi-
brosis in NASH, independently of insulin resistance, visceral
fat accumulation, serum TNF-α level, and dietary intake.
This finding agrees with the reported ability of adiponectin
to attenuate carbon tetrachloride–induced liver fibrosis in
mouse models (42). The suppressive effect of adiponectin
on platelet-derived growth factor- and transforming growth
factor-β1–induced proliferation and migration of cultured
hepatic stellate cells provides the molecular basis for the an-
tifibrotic effect of this novel adipokine (42).
Notably, the severity of hepatic steatosis and necroinflam-
mation did not correlate with fibrosis. Unlike fatty infiltration
and necroinflammation, which can be altered over a short pe-
riod of time in relation to lifestyle changes (i.e., diet, physi-
cal activity, hormonal status), fibrosis progression may occur
over a much longer period in NASH. Adipokine levels fluctu-
ate over time depending on the metabolic milieu as well. It is
therefore not surprising that cytokine levels measured in this
cross-sectional study correlated with the severity of histolog-
ical lesions, but there was no correlation between steatosis
necroinflammation and fibrosis. The finding that changes in
the severity of steatosis and inflammation run an independent
course from those of fibrosis has been reported in previous
studies (43, 13).
Serum TNF-α levels of our patients were comparable to
those of controls, although they correlated inversely with in-
sulin sensitivity and β-cell function This finding disagrees
in part with the existing data (13) and may suggest that the
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TNF-α pathway contributes to liver damage only at a later
stage or, alternatively, that serum TNF receptor 2 or tissue
TNF-α mRNA expression may be more sensitive markers of
TNF-α axis activation.
In conclusion, we found that β-cell dysfunction and hy-
poadiponectinemia are early features of NASH, appearing
well before glucose intolerance and/or the full picture of the
metabolic syndrome have developed and may contribute to
the progression of metabolic and liver disease to diabetes
and cirrhosis. Hypoadiponectinemia, in particular, may be a
link between impaired glucose homeostasis and liver disease,
thus providing the basis for the epidemiological association
between the metabolic syndrome and NASH and for a thera-
peutic strategy aimed at increasing circulating adiponectin in
this population. Other factors, such as increased TNF-α activ-
ity, may intervene later when overt obesity and glucose intol-
erance have appeared. Furthermore, the ability of adiponectin
levels to discriminate mild from severe forms of necroinflam-
mation and fibrosis may be useful in the clinical management
of NAFLD, allowing the selection of patients at higher risk for
progressive liver disease for liver biopsy and more aggressive
treatments. Given that larger trials are needed to confirm the
pathogenetic role of hypoadiponectinemia in both metabolic
and liver disease and to clarify the cause (genetic and/or ac-
quired) of hypoadiponectinemia, thiazolidinediones seem, at
present, to be a rational therapeutic choice in these patients,
given their ability to improve insulin sensitivity, restore β-
cell secretory function, divert fat from abdominal and liver
deposits, and increase serum adiponectin concentrations (44,
45).
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